Unither “will offer employment opportunities to the approximately 250 current employees (and 50 temporary staff),” Kristie Madara, a UCB spokeswoman, told us. “All current products will remain manufactured at the site as a result of this transaction so existing employees and temporary workers should be needed to continue to maintain current operations.”
The decision to continue to manufacture and produce UCB products comes through a multi-year supply agreement signed by the companies. Unither also intends to install as soon as possible BFS (blow, fill and seal) and stick-pack technologies in the Rochester plant to provide its clients or prospective clients with locally-made products.
According to Madara, products currently manufactured or packaged at the site include:
- Tussionex extended release suspension;
- Delsym extended release suspension;
- Metadate CD Capsules/Equasym XL capsules;
- Methylphenidate IR/ER tablets;
- Keppra tablets, oral solution and IV;
- Zaroxolyn (metolazone) tablets;
- Dipentum tablets and capsules;
- Cimzia LYO and pre-filled syringe; and
- Vimpat tablets, oral solution and IV.
“UCB will continue our strategy to focus on research and development, supply chain, and pilot-and-launch production activities in our two core therapeutic areas: neurology and immunology,” Madara said.
The transaction is expected to be completed in the fourth quarter of this year.